Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
William K. Kelly, Daniel C. Danila, Chia‐Chi Lin, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 76-89
Open Access | Times Cited: 23

Showing 23 citing articles:

The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 110
Cancer therapy with antibodies
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 43
A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 13
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Tanya B. Dorff, Lisa G. Horvath, Karen A. Autio, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1488-1500
Closed Access | Times Cited: 9
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies
Samir Zaidi, Jooyoung Park, Joseph M. Chan, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 28
Open Access | Times Cited: 8
Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles
Paola A. Castagnino, Derick A. Haas, Luca Musante, et al.
Cancer Biology & Therapy (2025) Vol. 26, Iss. 1
Open Access
Antikörper-Wirkstoff-Konjugate in der Uroonkologie
Christopher Darr, Thomas Hilser, Umut-Ulas Yesilyurt, et al.
Im Focus Onkologie (2025) Vol. 28, Iss. 1, pp. 20-25
Closed Access
T-cell Engagers in Prostate Cancer
Chadi Hage Chehade, Zeynep İrem Özay, Micah Ostrowski, et al.
European Urology (2025)
Closed Access
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Olivier Nolan-Stevaux, Cong Li, Lingming Liang, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 90-103
Closed Access | Times Cited: 13
T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer
Julia Palecki, Amman Bhasin, Andrew Bernstein, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 4
Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer
Chadi Hage Chehade, Georges Gebrael, Neeraj Agarwal
Cancer Discovery (2024) Vol. 14, Iss. 1, pp. 20-22
Closed Access | Times Cited: 1
Single Cell Analysis of Treatment–Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies
Samir Zaidi, Jooyoung Park, Joseph M. Chan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future
Harriet Lampe, Laura Tam, Aaron R. Hansen
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies
Laura H. Porter, Sophie Harrison, Gail P. Risbridger, et al.
The Journal of Steroid Biochemistry and Molecular Biology (2024) Vol. 243, pp. 106571-106571
Open Access | Times Cited: 1
Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies
Jingsong Zhang, Juskaran Chadha
Cancers (2024) Vol. 16, Iss. 17, pp. 3098-3098
Open Access | Times Cited: 1
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer Therapy
Prathap Nagaraja Shastri, Nirav N. Shah, Martin Lechmann, et al.
Clinical Pharmacology & Therapeutics (2024)
Closed Access | Times Cited: 1
A PSMA-targeted Tri-specific Killer Engager enhances NK cell cytotoxicity against prostate cancer
Shee Kwan Phung, Nicholas A. Zorko, Yvette Soignier, et al.
Cancer Immunology Research (2024) Vol. 13, Iss. 2, pp. 258-272
Closed Access | Times Cited: 1
Tumor-associated antigen targets for novel immune-based strategies in prostate cancer
Amman Bhasin, Patrick Mille, Aditya Eturi, et al.
Journal of Translational Genetics and Genomics (2024) Vol. 8, Iss. 1, pp. 55-76
Open Access
Clinical Applications of the Gut Microbiome in Genitourinary Cancers
Charles B. Nguyen, Ulka N. Vaishampayan
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access
Antikörper-Wirkstoff-Konjugate in der Uroonkologie
Christopher Darr, Thomas Hilser, Umut-Ulas Yesilyurt, et al.
Uro-News (2024) Vol. 28, Iss. 10, pp. 19-23
Closed Access
Mechanisms of Immune Evasion in PTEN Loss Prostate Cancer
Jorge Esteban-Villarrubia, Pablo Álvarez Ballesteros, Miguel Martín-Serrano, et al.
Immuno (2024) Vol. 4, Iss. 4, pp. 444-460
Open Access
Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies
Olivier Nolan-Stevaux, Richard Smith
Frontiers in Immunology (2024) Vol. 15
Open Access
Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies
Adam Khorasanchi, Karan Jatwani, Lingbin Meng, et al.
Cancers (2024) Vol. 16, Iss. 24, pp. 4127-4127
Open Access
Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management
Jie Chen, Na Ma, Bo Chen, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 207, pp. 104604-104604
Open Access
Page 1

Scroll to top